At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Pre-Mkt 02-05 04:18:54 EST
5.13
-0.34
-6.22%
盘前5.15
+0.02+0.39%
04:05 EST
High5.53Low5.09Vol3.56M
Open5.47D1 Closing5.47Amplitude8.14%
Mkt Cap642.44MTradable Cap636.12MTotal Shares125.23M
T/O18.59MT/O Rate2.87%Tradable Shares124.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Novo Nordisk Warns on Profits and Sales Amid Trump Drug Price Crackdown
Reuters  ·  02-04 01:15
Novo Nordisk Warns on Profits and Sales Amid Trump Drug Price Crackdown
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
THOMSON REUTERS  ·  01-30
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target
MT Newswires Live  ·  01-28
Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline
TIPRANKS  ·  01-28
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline
Altimmune prices $75M registered direct offering
TIPRANKS  ·  01-28
Altimmune prices $75M registered direct offering
Altimmune Raises $75 Million in Direct Offering of Shares and Pre-Funded Warrants
Reuters  ·  01-28
Altimmune Raises $75 Million in Direct Offering of Shares and Pre-Funded Warrants
Altimmune initiated with an Overweight at Barclays
TIPRANKS  ·  01-28
Altimmune initiated with an Overweight at Barclays
Libevitug Approved in China as First-in-Class Hepatitis D Treatment
prnewswire  ·  01-27
Libevitug Approved in China as First-in-Class Hepatitis D Treatment
Altimmune (ALT) Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation
Simply Wall St.  ·  01-27
Altimmune (ALT) Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation
Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial
Simply Wall St.  ·  01-26
Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial
Altimmune call volume above normal and directionally bullish
TIPRANKS  ·  01-23
Altimmune call volume above normal and directionally bullish
CCL Industries to Acquire ALT Technologies, Expanding Automotive Safety Business
TIPRANKS  ·  01-16
CCL Industries to Acquire ALT Technologies, Expanding Automotive Safety Business
Altimmune Director Wayne Pisano Acquires Common Shares
Reuters  ·  01-10
Altimmune Director Wayne Pisano Acquires Common Shares
Owens & Minor Issues Amended Report on P&HS Business Sale
Reuters  ·  01-06
Owens & Minor Issues Amended Report on P&HS Business Sale
Altimmune Inc. Director Catherine A. Sohn Reports Acquisition of Common Shares
Reuters  ·  01-06
Altimmune Inc. Director Catherine A. Sohn Reports Acquisition of Common Shares
BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
Reuters  ·  01-06
BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
Benzinga_recent_news  ·  01-05
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
Shares of Altimmune Rise 21.4% After US FDA's 'Breakthrough' Tag for Liver Disease Drug
THOMSON REUTERS  ·  01-05
Shares of Altimmune Rise 21.4% After US FDA's 'Breakthrough' Tag for Liver Disease Drug
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive
Reuters  ·  01-05
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive
BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug
Reuters  ·  01-05
BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug

Introduction

Company Name.
Altimmune, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Issue price:
--